Novel EP1 receptor antagonists

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 3, 2004, Pages 435-438

[No Author Info available]

Author keywords

Cancer; Cyclopentene; EP1 receptor; Inflammation; Pain; Prostaglandin (PG)E2

Indexed keywords

1 ACETYL 2 (8 CHLORO 10,11 DIHYDRODIBENZ[B,F][1,4]OXAZEPINE 10 CARBONYL)HYDRAZINE; 6 [3 (4 CHLORO 2 METHYLPHENYLSULFONYLAMINOMETHYL)BICYCLO[2.2.2]OCTAN 2 YL] 5 HEXENOIC ACID; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; [2 (2 BENZYLOXYPHENYL)CYCLOPENT 1 ENYL]; CARBOXYLIC ACID DERIVATIVE; PROSTAGLANDIN E1; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTANOID; PROSTANOID RECEPTOR; SC 51322; UNCLASSIFIED DRUG; ZD 4953; ZD 6416; ZD 6840;

ANALGESIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; PAIN; PATENT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

EID: 1642358392     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/eotp.14.3.435.27473     Document Type: Article

References (7)

1. COLEMAN RA, SMITH, WL, NARUMIYA S: International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. (1994) 46:205-229.
2. ABRAMOVITZ M, ADAM M, BOIE Y et al.: The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta. (2000) 1483(2):285-293.
3. 1 prostanoid receptor. Mol. Pharmacol. (2001) 59:1446-1456.
4. 1 receptor subtype selectivity takes shape. Mol. Pharmacol. (2001) 59:1357-1359.
5. 2 antagonist. Bioorg. Med. Chem. (2001) 9(1):1-6.
6. 2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. (2003) Gastroenterology 124(1):18-25.
7. KAWAMORI T, UCHIYA N, KITAMURA T et al.: Evaluation of a selective prostaglandin E receptor EP1 antagonist for potential properties in colon carcinogenesis. Anticancer Res. (2001) 21(6A):3865-3869.